300
Views
73
CrossRef citations to date
0
Altmetric
Original

Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief

, , , &
Pages 120-131 | Received 25 Aug 2006, Accepted 05 Jan 2007, Published online: 03 Jul 2009
 

Abstract

Objective To evaluate the efficacy of two ultra-low-dose 17β-estradiol plus norethisterone acetate (NETA) treatment regimens for relieving menopausal symptoms.

Design A total of 577 postmenopausal women were enrolled, in three treatment groups in a double-blind, randomized, placebo-controlled study of 0.5 mg 17β-estradiol + 0.1 mg NETA or 0.5 mg 17β-estradiol + 0.25 mg NETA or placebo. Participants returned at weeks 4, 8, 12 and 24 for climacteric complaint evaluation based on a daily diary vasomotor symptom record. Patients were assessed by the Greene Climacteric Scale and urogenital symptoms were also evaluated.

Results Treatment with ultra-low-dose 0.5 mg 17β-estradiol + 0.1 mg NETA (0.1 Group) or 0.5 mg 17β-estradiol + 0.25 mg NETA (0.25 Group) effectively reduced the severity and number of hot flushes within the initial weeks of therapy. Compared to placebo, a rapid, statistically significant decrease in the frequency and severity of hot flushes was achieved by week 3, followed by further improvement which continued throughout the study. There were no statistically significant differences between the active treatment arms.

Conclusions The data show that both ultra-low-dose regimens are effective in reducing the severity and number of hot flushes compared to placebo, with good safety profiles.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.